Vallejo E

Language: Spanish
References: 19
Page: 220-225
PDF size: 64.26 Kb.

ABSTRACT

Positron emission tomography (PET) is an intrinsically quantitative method that provides an approach for the clinical cardiologist and cardiovascular researchers to evaluate the heart noninvasively. The ability to label biomolecules with positron-emiting radioisotopes, without disturbing their physiological properties, offers the opportunity to prove and quantify coronary blood flow, myocardial metabolism, and the alterations that occur with disease states. However, the major drawback prohibiting implementation of PET imaging in clinical routine is the limited availability of PET equipment and its greater cost per study.
In order to enhance cost savings and resource efficiency in clinical practice, PET studies should be limited to those patients with equivocal studies by other imaging modalities or to define areas of potential viability and improve decisions for recommending coronary bypass grafting or cardiac transplantation. The combined data of multiple investigators suggest that 18-FDG-SPECT imaging may become the protocol of choice for determining myocardial viability because of its increased availability and cost-effectiveness as compared to PET.

REFERENCES

1. Tewson TJ, Krohn KA: PET radiopharmaceuticals: state-of-the-art and future prospects. Sem Nucl Med 1998; 38: 221-234.

2. Budinger TF: PET instrumentation: What are the limits? Sem Nucl Med 1998; 38: 247-267,

3. Galt JR, Cullom J, García E: Attenuation and scatter compensation in myocardial perfusion SPECT. Sem Nucl Med 1998; 38: 204-220.

4. Srinivasan G, Kitsiou AN, Bacharach SL, Barlett ML, Miller-Davis C, Dilsizian V: 18(F]luorodeoxyglucose single photon emission computed tomography: can it replace PET and thallium SPECT for the assessment of myocardial viability? Circulation 1998; 97: 843-50.

5. Bergmann SR: Cardiac positron emission tomography. Sem Nucl Med 1998; 38: 320-340.

6. Arrighi JA: F-18 fluorodeoxuglucose imaging in myocardial ischemia: beyond myocardial viability. J Nucl Cardiol 2001; 8: 417-20.

7. Siebelink HM: No difference in cardiac event-free survival between PET-guided and SPECT-guided patient managment. J Am Coll Cardiol 2001; 37: 81-88.

8. Rohatgi R, Epstein S, Henriquez J, Ababneh A, Hickey KT, Pinsky D, et al: Utility of Positron Emission Tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction. Am J Cardiol 2001; 87: 1096-1099.

9. Schelbert HR: Cardiac PET: microcirculation and substrate transport in normal and disease human myocardium. Annals of Nuclear Medicine 1996; 8: 91-100.

10. Arrighi JA, Burg M, Cohen IS, Kao AH, Pfau S, caulin-glaser t, et al: Myocardial blood-flow response during mental stress in patients with coronary artery disease. Lancet 2000; 356: 310-311.

11. Auerbach MA, Schöder H, Hoh C, Gambhir SS, Yaghoubi S, sayre jw, et al: Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy. Circulation 1999; 99: 2921-2926.

12. Sklenar J, Camarano G, Goodman C, Ismail S, Jayaweera AR, kaul s: Contractile versus microvascular reserve for the determination of the extent of myocardial salvage after reperfusion. The effect of residual coronary stenosis. Circulation 1996; 94: 14430-1440.

13. Gerber BL, Vanoverschelde JLJ, Bol A, Michel C, Labar D, wijns w, et al: Myocardial blood flow, glucose uptake, and recruitment of inotropic reserve in chronic left ventricular ischemic dysfunction. Implications for the pathophysiology of chronic myocardial hibernation. Circulation 1996; 94: 651-659.

14. Panza JA, Dilsizian V, Curiel RV, Unger EF, Laurienzo JM, kitsiou an: Myocardial blood flow at rest and contractile reserve in patients with chronic artery disease and left ventricular dysfunction. J Nucl Cardiol 1999; 6: 487-94.

15. Ragosta M, Powers ER, Samady H, Gimple L, Sarembock IJ, Beller G: Relationship between extent of residual myocardial viability and coronary flow reserve in patients with recent myocardial infarction. Am Heart J 2001; 141: 456-62.

16. Baumgartner H, Porenta G, Lau YK, Wutte M, Klaar U, Mehrabi M, et al: Assessment of myocardial viability by dobutamine echocardiography, positron emission tomography and thallium-201 SPECT. Correlation with hystopathology in explanted hearts. J Am Coll Cardiol 1998; 32: 1701-8.

17. Dilsizian V: Fluorine 18-fluorodeoxyglucose SPECT and coincidence imaging for myocardial viability: clinical and technologic issues. J Nucl Cardiol 2001; 8: 75-88.

18. Kerrou K, Toussaint JF, Froissart M, Talbot JN: Myocardial viability assessment with FGD imaging: comparison of PET, SPECT, and gamma-camera coincidence detection. J Nucl Med 2000; 41: 2099-2100.

19. Sandler M, Patton JA: Fluorine 18-labeled fluorodeoxyglucose myocardial single photon emission computed tomography: an alternative for determining myocardial viability. J Nucl Cardiol 1996; 3: 342-9.